‘Cancer Miasm’ And The Role Of Cancer Nosodes In The Treatment Of Chronic Diseases
by Chandran Nambiar i
Shall we consider a ‘cancer miasm’? This question is frequently asked whenever the topic ‘miasms’ is discussed. Since hahnemann has talked about only three chronic miasms (psora, syphilis and sycosis), ‘classical’ homeopaths will not agree to the proposals regarding new miasms other than these three. But some homeopaths talk about miasms such as tuberculous, typhoid, vaccinosis, cancer, malaria etc etc.
According to my interpretation of miasms as chronic disease dispositions caused by off-target actions of anti-bodies generated against ‘alien proteins’ such as infectious agents, we need not limit the number of miasms in three hahnemann explained. Any infectious disease that can generate antibodies in the organism can act as a causative factor of chronic miasms. Vaccinations, which induce production of anti-bodies in the organism, have to be considered as miasmatic factors. More over, history of allergic reactions towards any ‘alien proteins’ entering the organism, such as various allergens, bites and stings of insects and serpents, and anaphylactic reactions also have to be considered as ‘miasms’.
How can we explain the concept of ‘cancer miasm’ from this ‘anti-body’ view point?
Cancer is not an infectious disease, or it does not involve ‘alien’ proteins entering from outside. But, we know, cancer cells contain some mutant genes that are different from ‘native genetic substance’ of organism. These mutant genes can synthesize proteins that are in fact ‘alien’ to the immune system of organism, and antibodies will be produced against these ‘alien’ proteins. In most cases, cancer cells will be destroyed by the immune system before the appearance of observable cancer manifestations. But, these antibodies remain, and will act as miasms, by their ‘off-target’ actions upon various bilogical molecules. As such, ‘cancer miasm’ is a reality.
But it is obvious that there cannot be ‘cancer miasm’ without an immune process happened against ‘cancer’ proteins at any point of time in the individual’s life history. We should remember, our genetic material may anytime go astray due to the action of various environmental factors such as carcinogenic substances and ionizing radiations to which we are constantly exposed. Metabolic bye-products such as free radicals, which are regularly produced in our body, may also create mutations in our genes. Such mutant genes may lead to the production of cancerous cells, which are constantly identified, located, entrapped and destructed by the scavengers of our immune system. These mutant cells grow into cancer disease only in very rare occasions, when our immune system fail in its duties. That means, production and destruction of mutant genes and cancer cells are a constant process in the organism.
Destruction of mutant genes and cancer cells involves production of antibodies also against the proteins synthesized by them. These ‘cancer antibodies’ will remain in the system even after ‘cancer cells’ are destroyed. These antibodies generated against ‘alien’ proteins synthesized by mutant genes can travel in the organism, migrate to different parts and may bind to various biological molecules having configurational affinity. Such ‘off-target’ bindings lead to molecular inhibitions of biological molecules, which amount to molecular level pathologies similar to any miasmatic chronic disease. That means, antibodies generated against cancer cells would act as ‘cancer miasms’, causing disease dispositions of chronic nature. Obviously, not only in persons of known history of cancer, but almost all seemingly ‘cancer-free’ people may carry cancer antibodies.
Cancer antibodies, or cancer miasms can be effectively combated using cancer nosodes such as ‘carcinocin’, ‘schirinum’ etc, which are potentized cancer products, which would contain molecular imprints of ‘cancer proteins’ as well as ‘cancer antibodies’. Molecular imprints of cancer antibodies act therapeutically by competing with cancer antibodies in binding to the biological molecules, where as molecular imprints of cancer proteins directly bind to the cancer proteins themselves. Molecular imprints cannot interfere in the interactions of antibodies with cancer cells, as they are their natural ligands. That means, even while rectifying the ‘miasmatic’ effects of cancer antibodies, carcinocin nosode will not by any way reduce the anti-cancer fight of our immune system.
This study clearly shows the importance of regular use of cancer nosodes in the management of various diseases of chronic nature.